drugset / Trial / NCT03907098

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

NCT03907098

Phase 2 Unknown 50 enrolled Zhejiang Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This research study is studying endostar in combination with chemotherapy as a possible treatment for HER-2 negative advanced breast cancer.

Timeline

Start
2016-06-30
Primary completion
2019-12-30
Completion
2020-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Endostar Protein / enzyme biologic 15 mg/m2 Intravenous

Indications